What is it about?
The research is about formulating gentamicin as self-nanoemulsifying formulations (SNEFs) for oral administration and treating it with polyethylene glycol 4000 so as to increase its systemic circulation due to relative invisibility imparted to the formulations. As a result, these formulations improved the ability of the SNEFs as the carrier system to ferry gentamicin across the blood-brain barrier and dock it in the cerebrospinal fluid of rats infected with Streptococcus pneumoniae. Finally, the gentamicin SNEFs showed improved activity against the bacteria compared with free gentamicin solution.
Featured Image
Why is it important?
The uniqueness of the work stems from the fact that this is the first time self-nanoemulsifying technology was used for improved delivery of gentamicin. Surface modification of the delivery system further improved its performance in vivo due to the invisibility imparted to gentamicin in the systemic circulation thereby increasing its circulation time, and discouraging its expulsion from the systemic circulation by the efflux factors in the rats. The formulation designed to encapsulate low dose gentamicin was docked in the cerebrospinal fluid across the blood-brain barrier, and inhibited Streptococcus pneumoniae.
Perspectives
The work is novel, scholarly and contemporary. It represents a paradigm shift from ordinary reports of administration of gentamicin injections and withdrawing blood for analysis.
Dr Chukwuebuka Emmanuel Umeyor
Nnamdi Azikiwe University
Read the Original
This page is a summary of: Formulation of gentamicin as surface modified self-nanoemulsifying formulations (SNEFs) improves its anti-pneumococcal activity, European Journal of Nanomedicine, January 2016, De Gruyter,
DOI: 10.1515/ejnm-2015-0037.
You can read the full text:
Contributors
The following have contributed to this page
